Search form


Press Releases

Axcan Pharma to Present at Scotia Capital Pharmaceutical and Biotechnology Conference in Toronto

Apr 20, 2005 - 12:00 ET

MONT SAINT-HILAIRE, QC, April 20 - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that on Tuesday, April 26, 2005,
its Executive Vice-President and Chief Operating Officer, David W. Mims, will
present an overview of the Company at the Scotia Capital Healthcare and
Biotechnology Conference held in Toronto. This presentation will take place at
9:45 A.M. ET.
Interested parties can access the audio webcast of the presentation on
the Company's website at .

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".


    "Safe Harbor" statement under the Private Securities Litigation Reform
    Act of 1995.


To the extent any statements made in this release contain information
that is not historical, these statements are essentially forward looking and
are subject to risks and uncertainties, including the difficulty of predicting
FDA and other regulatory approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing, new
product development and launch, reliance on key strategic alliances,
availability of raw materials, the regulatory environment, fluctuations in
operating results and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission and the Canadian
Multijurisdictional Disclosure System.

Julie M. Thibodeau, Manager, Investor 
Relations, Axcan Pharma Inc., (450) 467-5138, ext. 2062,; 
Source: Axcan Pharma Inc.